FDA PMA (Premarket Approval) Guide: Process, Fees, Supplements and Post-Approval Duties

Premarket Approval (PMA) is the most demanding marketing pathway FDA has for medical devices. It applies to Class III devices that support or sustain human life, are of substantial importance in preventing impairment of health, or present a potential unreasonable risk of illness or injury, and for which no valid predicate exists. Unlike a 510(k), a PMA does not show equivalence to another device: it requires valid scientific evidence, usually including clinical data, that the device is safe and effective for its intended use. This guide explains how a PMA is structured, how the review runs, what it costs and what happens after approval.

When a PMA is required

A device needs a PMA when it is Class III and either has no predicate for a 510(k) or is a type that FDA has specifically called for PMAs for under its classification regulations. Typical examples are implantable heart valves, pacemakers, certain neurostimulators and some high-risk diagnostics. Lower-risk novel devices may instead use the De Novo pathway, and devices with a predicate use the 510(k) process. Our overview of US FDA medical device regulations shows where PMA fits.

Types of PMA

• Traditional PMA: one complete application with all sections.
• Modular PMA: sections (for example preclinical, manufacturing, clinical) submitted and reviewed in stages. It can reduce risk on a long project.
• Product Development Protocol (PDP): an agreed development protocol that, once completed, is deemed approved. It is rare but useful for well-understood technologies.
• Humanitarian Device Exemption (HDE): a separate pathway for devices for rare conditions, with a different effectiveness standard and restrictions on use and profit.

What a PMA contains

Section	Content
Device description and intended use	Design, materials, principle of operation, indications for use, contraindications
Nonclinical studies	Bench and performance testing, biocompatibility, sterilisation, shelf life, software, electrical and EMC safety, animal studies
Clinical studies	Study protocol, results, statistical analysis, adverse events, subject disposition, and a benefit-risk assessment. See IDE and device clinical studies
Manufacturing information	Processes, facilities, controls, and the quality system, including process validation. See process validation
Labelling	Proposed labels, instructions for use and patient information. See FDA labelling requirements
Other	Summary of safety and effectiveness data, financial disclosure, references, and environmental assessment where applicable

The review process

1. Pre-submission interaction. Use a Q-Submission early to agree the clinical design, endpoints and statistical plan. Many PMA problems come from an unagreed study.
2. Filing review. FDA decides within about 45 days whether the application is complete enough to review. A refusal to file is costly.
3. Substantive review. Reviewers send deficiency questions. The response time counts against your schedule, even though the statutory review clock pauses.
4. Advisory panel. FDA may take the application to an advisory panel, particularly for novel technology or contested benefit-risk.
5. Quality system inspection. FDA inspects the manufacturing sites. Since 2 February 2026 the inspection is against the QMSR, which incorporates ISO 13485. See FDA QSIT inspections.
6. Decision. FDA issues an approval order (often with conditions), an approvable letter, a not-approvable letter or a denial.

Fees

User fees are set each fiscal year. For FY2027 (1 October 2026 to 30 September 2027), the published standard fees include:

Submission	Standard fee	Small business fee
Original PMA	$636,732	$159,183
Panel-track supplement	$509,386	$127,347
180-day supplement	$95,510	$23,878
Real-time supplement	$44,571	$11,143
Annual establishment registration	$13,785	$13,785 (waiver possible)

Small business status needs to be approved before you pay, so apply in good time. Fees are only a fraction of the real cost: the clinical study is normally the largest budget item.

After approval

• PMA supplements: changes affecting safety or effectiveness, such as design, materials, manufacturing site, sterilisation or labelling, need a supplement. Types include panel-track, 180-day, real-time, special (changes being effected) and 30-day notices. Use a structured change control process to decide which applies.
• Annual reports: required, with information on changes and on post-market performance.
• Post-approval studies: often a condition of approval, to follow long-term outcomes or a broader population.
• Adverse event and recall reporting: see Medical Device Reporting and recalls.
• Unique Device Identification: see UDI.
• Reimbursement: plan coverage and payment in parallel. See US device reimbursement.

Common mistakes

• Starting a pivotal study before agreeing the endpoints and statistical plan with FDA.
• Not building manufacturing readiness (validated processes, supplier controls) into the timeline.
• Submitting a PMA with gaps that lead to a refusal to file.
• Underestimating the effort of the deficiency response phase.
• Treating post-approval conditions as an afterthought.
• Changing the device or process during review without an amendment strategy.

Frequently asked questions

How long does a PMA take?

The statutory review period is 180 days, but typical real timelines are much longer because of deficiency questions, panel meetings and inspections. Plan on many months to years from filing, and begin the quality system work early.

Can I use data from outside the US?

Yes, if the data are valid, the population and practice are applicable to the US, and FDA can verify the study conduct. Agree the approach in a Q-Submission.

What is the difference between PMA and 510(k)?

A 510(k) shows substantial equivalence to a predicate. A PMA shows reasonable assurance of safety and effectiveness on its own evidence, usually including clinical data, and it ends in an approval rather than a clearance.

Can AI-enabled devices go through PMA?

Yes, if they are Class III. See AI-enabled devices and PCCP for how planned algorithm changes can be handled.

FDA fees, guidance and review practice change. Confirm current requirements and the fee schedule with FDA and your regulatory advisers before you act on this guide.

Related reading

• US FDA medical device regulations: classification and pathways.
• FDA Breakthrough Devices Program: faster interaction for qualifying PMA devices.
• IDE and device clinical studies: the evidence behind a PMA.
• FDA De Novo guide: the alternative for novel lower-risk devices.
• Design controls: the design file FDA will inspect.

Talk to the AptSkill team

Preparing a PMA or building FDA regulatory skills? Send us your device type and goal.